Ipsen S.A. is a pharmaceutical company. It provide drugs for urology, oncology, endocrinology, neurology, gastroenterology, cognitive disorders, rheumatology and cardiovascular. Ipsen S.A. is headquartered in Boulogne-Billancourt, France.
| Revenue (Most Recent Fiscal Year) | $3.87B |
| Net Income (Most Recent Fiscal Year) | $374.30M |
| PE Ratio (Current Year Earnings Estimate) | 10.49 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 12.08% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 1.34 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.15 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $2.78 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 335.26M |
| Free Float | -- |
| Market Capitalization | $9.70B |
| Average Volume (Last 20 Days) | 1450.35 |
| Beta (Past 60 Months) | 0.54 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.21 |
| Dividend Yield (Based on Last Quarter) | 0.73% |